文献速递炎症性肠病

G9a调控CD4 T细胞脂质代谢以调节肠道炎症

G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation.
PubMed 文献 · Gastroenterology · 2022-10-20

研究探讨G9a在人类CD4 T细胞分化中的作用及靶向G9a治疗炎症性疾病的潜力。体外实验显示G9a抑制剂UNC0642促进FOXP3+调节性T细胞(Treg)生成,机制涉及脂质合成基因转录改变和细胞内胆固醇升高;三种小鼠模型证实G9a抑制可体内扩增Treg并缓解结肠炎。

要点

  • G9a抑制剂UNC0642在体外促进人CD4 T细胞自发分化为FOXP3+ Treg。
  • G9a抑制改变T细胞脂质合成基因转录,增加细胞内胆固醇。
  • 小鼠模型中G9a抑制促进抗原刺激下Treg扩增并缓解急性TNBS诱导结肠炎。

核心结论

  • G9a抑制促进T细胞胆固醇代谢,形成有利于Treg发育的代谢特征,数据支持G9a抑制剂用于治疗包括炎症性肠病在内的免疫介导疾病的潜力。

研究设计与样本

  • 体外研究:从外周血分离人初始T细胞,在G9a抑制剂UNC0642存在下体外分化,并通过转录组(RNA测序)、染色质可及性(ATAC-seq)、蛋白表达(CyTOF、流式细胞术)、代谢(线粒体压力测试、UPLC-MS/MS)和功能(T细胞抑制实验)进行表征。
  • 体内研究:使用3种小鼠模型评估G9a的作用。

主要发现

  • 药物抑制G9a酶功能导致人CD4 T细胞体外自发产生FOXP3+ T细胞(G9a抑制剂诱导的Treg),功能和表型上忠实再现人Treg。
  • G9a抑制改变T细胞中脂质生物合成相关基因的转录调控,导致细胞内胆固醇增加。
  • G9a抑制剂诱导的Treg代谢组学分析证实脂质通路升高,通过氧化磷酸化和增强脂质膜组成支持Treg发育。
  • 药物抑制G9a在抗原(麦胶蛋白)刺激下促进体内Treg扩增,并继发于组织特异性Treg发育而改善急性三硝基苯磺酸诱导的结肠炎。
  • 缺乏G9a表达的Treg(G9a敲除Treg)长期保持功能,并能挽救T细胞转移诱导的结肠炎。

临床怎么用

  • 作者认为数据支持G9a抑制剂在治疗包括炎症性肠病在内的免疫介导疾病中的潜在用途。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although T-cell intrinsic expression of G9a has been associated with murine intestinal inflammation, mechanistic insight into the role of this methyltransferase in human T-cell differentiation is ill defined, and manipulation of G9a function for therapeutic use against inflammatory disorders is unexplored. METHODS: Human naive T cells were isolated from peripheral blood and differentiated in vitro in the presence of a G9a inhibitor (UNC0642) before being characterized via the transcriptome (RNA sequencing), chromatin accessibility (assay for transposase-accessible chromatin by sequencing), protein expression (cytometry by time of flight, flow cytometry), metabolism (mitochondrial stress test, ultrahigh performance liquid chromatography-tandem mas spectroscopy) and function (T-cell suppression assay). The in vivo role of G9a was assessed using 3 murine models. RESULTS: We discovered that pharmacologic inhibition of G9a enzymatic function in human CD4 T cells led to spontaneous generation of FOXP3+ T cells (G9a-inibitors-T regulatory cells [Tregs]) in vitro that faithfully reproduce human Tregs, functionally and phenotypically. Mechanistically, G9a inhibition altered the transcriptional regulation of genes involved in lipid biosynthesis in T cells, resulting in increased intracellular cholesterol. Metabolomic profiling of G9a-inibitors-Tregs confirmed elevated lipid pathways that support Treg development through oxidative phosphorylation and enhanced lipid membrane composition. Pharmacologic G9a inhibition promoted Treg expansion in vivo upon antigen (gliadin) stimulation and ameliorated acute trinitrobenzene sulfonic acid-induced colitis secondary to tissue-specific Treg development. Finally, Tregs lacking G9a expression (G9a-knockout Tregs) remain functional chronically and can rescue T-cell transfer-induced colitis. CONCLUSION: G9a inhibition promotes cholesterol metabolism in T cells, favoring a metabolic profile that facilitates Treg development in vitro and in vivo. Our data support the potential use of G9a inhibitors in the treatment of immune-mediated conditions including inflammatory bowel disease.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ramos GP, Bamidele AO, Klatt EE, et al. G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation. Gastroenterology. 2022. PMID: 36272457. doi:10.1053/j.gastro.2022.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。